Products for Research Use Only
RegisterLogin

Sampatrilat

CAT: 0804-HY-123348-01Size: 5 mgDry Ice: NoHazardous: No
Product image 1
1 / 1
CAT#:0804-HY-123348-01Size:5 mg
Selected
24/48H Stock Items & 2 to 6 Weeks non Stock Items.
Quick Request Actions
Description
Sampatrilat (UK-81252) is a potent and orally active vasopeptidase inhibitor of ACE and neutral endopeptidase (NEP) . Sampatrilat inhibits C-domain ACE (Ki=13.8 nM) 12.4-fold more potent than that for the N-domain (Ki=171.9 nM) . Sampatrilat (UK-81252) can be used for the study of chronic heart failure and blood pressure regulation[1][2].
CAS Number
129981-36-8
Product Name Alternative
UK-81252
UNSPSC
12352005
Hazard Statement
H302-H312-H332
Target
Angiotensin-converting Enzyme (ACE) ; Neprilysin
Type
Reference compound
Related Pathways
Metabolic Enzyme/Protease
Applications
COVID-19-anti-virus
Field of Research
Inflammation/Immunology; Cardiovascular Disease
Assay Protocol
https://www.medchemexpress.com/sampatrilat.html
Purity
99.22
Solubility
DMSO : 100 mg/mL (ultrasonic)
Smiles
OC([C@H](CNC([C@@H](NS(C)(=O)=O)CCCCN)=O)CC1(CCCC1)C(N[C@H](C(O)=O)CC2=CC=C(O)C=C2)=O)=O
Molecular Formula
C26H40N4O9S
Molecular Weight
584.68
Precautions
P261-P264-P270-P271-P280-P302+P352-P304+P340-P330-P363-P501
References & Citations
[1]Sharma RK, et al. The Dynamic Nonprime Binding of Sampatrilat to the C-Domain of Angiotensin-Converting Enzyme. J Chem Inf Model. 2016 Dec 27;56 (12) :2486-2494.|[2]Maki T, et al. Beneficial effects of sampatrilat, a novel vasopeptidase inhibitor, on cardiac remodeling and function of rats with chronic heart failure following left coronary artery ligation.J Pharmacol Exp Ther. 2003 Apr;305 (1) :97-105.
Shipping Conditions
Blue Ice
Storage Conditions
-20°C (Powder, sealed storage, away from moisture)
Scientific Category
Reference compound1
Clinical Information
Phase 2

Alternative Products

CatalogName
GTR19203130-01Sampatrilat

Popular Products